Indeed, the use of OX40L antibodies can effectively inhibit the proliferation of CD4+OX40+T cells in the ovalbumin-induced asthma mouse model and may further reduce the inflammatory response by altering the secretion of IL-4, IL-6, IL-13, IL-17, and TNF-α, and IFN-γ, and thus alleviate the progression of asthma (94). The gene discussed is IL13; the disease is asthma.